公开(公告)号：US20140107016A1

公开(公告)日：2014-04-17

申请号：US14138449

申请日：2013-12-23

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein ,  Thomas J. Podsadecki

IPC: A61K38/12 ,  A61K31/427 ,  A61K31/7072 ,  A61K31/4184 ,  A61K31/4025 ,  A61K31/513

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/473 ,  A61K31/513 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/06 ,  A61K38/12 ,  A61K45/06 ,  G06F17/10 ,  G06F19/12

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

公开(公告)号：US20240115650A1

公开(公告)日：2024-04-11

申请号：US18534967

申请日：2023-12-11

Applicant: ABBVIE INC.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220288153A1

公开(公告)日：2022-09-15

申请号：US17484287

申请日：2021-09-24

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US08685984B2

公开(公告)日：2014-04-01

申请号：US13935987

申请日：2013-07-05

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein ,  Thomas J. Podsadecki

IPC: A61K31/4965 ,  A61K31/505 ,  A61K31/47 ,  A61K31/415 ,  A61K31/40 ,  A61K31/675

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/473 ,  A61K31/513 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/06 ,  A61K38/12 ,  A61K45/06 ,  G06F17/10 ,  G06F19/12

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

公开(公告)号：US08680106B2

公开(公告)日：2014-03-25

申请号：US13935983

申请日：2013-07-05

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein ,  Thomas J. Podsadecki

IPC: A61K31/4965 ,  A61K31/505 ,  A61K31/47 ,  A61K31/415 ,  A61K31/40 ,  A61K31/675

CPC classification number: A61K38/07 ,  A61K31/402 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/12 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Abstract translation: 本发明的特征在于用于治疗HCV的无干扰素治疗。 优选地，治疗过程持续时间较短，例如不超过12周。 在一个方面，治疗方法包括向具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3），细胞色素P450抑制剂（例如利托那韦）和利巴韦林。

公开(公告)号：US20240232171A1

公开(公告)日：2024-07-11

申请号：US18613308

申请日：2024-03-22

Applicant: ABBVIE INC.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: G06F16/23 ,  G06F7/00 ,  G06F16/215 ,  G06F16/25

CPC classification number: G06F16/2365 ,  G06F7/00 ,  G06F16/215 ,  G06F16/2379 ,  G06F16/252

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20180177779A1

公开(公告)日：2018-06-28

申请号：US15738773

申请日：2016-07-07

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K31/498 ,  A61K31/454 ,  A61K31/7072 ,  A61P31/14

CPC classification number: A61K31/498 ,  A61K31/454 ,  A61K31/7056 ,  A61K31/7072 ,  A61P31/14 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20180042982A1

公开(公告)日：2018-02-15

申请号：US15782162

申请日：2017-10-12

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Tami Pilot-Matias ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Lino Rodrigues Junior ,  Suvajit Samanti ,  Roger Trinh ,  Tianli Wang ,  Betty B. Yao

IPC: A61K38/06 ,  A61K31/7072 ,  A61K31/4184 ,  A61K31/7056

CPC classification number: A61K38/06 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

Abstract: The present invention generally features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. Further, additional compounds such as sofosbuvir, or its pharmaceutically acceptable salt may be used for retreatment of HCV patients who have failed glecaprevir and pibrentasvir combination therapy.

公开(公告)号：US20170151238A1

公开(公告)日：2017-06-01

申请号：US15431906

申请日：2017-02-14

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K31/498 ,  A61K31/454

CPC classification number: A61K31/498 ,  A61K31/454 ,  A61K38/05 ,  A61K38/06 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20160333404A1

公开(公告)日：2016-11-17

申请号：US14557524

申请日：2014-12-02

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Isabelle A. Gaultier ,  Daniel E. Cohen ,  Jeffrey F. Waring ,  Stephen J. Abel ,  Emily O. Dumas

IPC: C12Q1/68 ,  A61K31/497 ,  A61K31/513 ,  A61K31/7056

CPC classification number: A61K31/513 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K31/7056 ,  A61K38/212 ,  A61K45/06 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/178 ,  A61K2300/00

Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine expression levels of microRNAs such as miR-122 or miR-21. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Abstract translation: 本发明的特征在于治疗包含直接作用的抗病毒剂的HCV的治疗。 优选地，将治疗施用于经过测试以确定微小RNA如miR-122或miR-21的表达水平的HCV感染患者。 在一个方面，治疗方法包括向具有HCV感染的受试者施用一种或多种直接作用的抗病毒剂和任选的利巴韦林。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2，细胞色素P450的抑制剂（例如利托那韦）和利巴韦林。